meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced NSCLC - (neo)adjuvant (NA)
1
laNSCLC - NA - all population
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab plus SoC